Biologic therapies for inflammatory bowel disease are cost-effective, providing significant health benefits that offset higher costs. Substantial methodological heterogeneity and reliance on model-based economic evaluations limit direct comparability across studies. Future economic evaluations should focus on methodological consistency and transparency in assumptions to strengthen the interpretability of cost-effectiveness evidence.
Randlová et al. (Fri,) studied this question.